Nephrology - What's Next?

After 25 years of really just having ras blockade, we're really excited about some novel therapies. In 20 19, the credence trial was the first dedicated renal outcome trial with staltitwo inhibitors. To this study randomized patients to kanagla floesan, one of the talti two inhibitors, compared to placibo. And they showed a 30 % reduction in the primary renal n point of doubling of cerum,. cran in e, s k d or renal or carti vascular death. The other new class that is probably going to be positive, but we're waiting for the final results, is a drug called ronone. There's also a fideln